Peter Jackson, Infex Therapeutics executive director
Scoop: Infectious disease biotech eyes $25M Series A to advance antibody for chronic lung infection
Infex Therapeutics is planning to raise up to £20 million ($25 million) in a Series A round with an eye to progressing its lead asset …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
